Lv11
50 积分 2023-06-12 加入
Tafasitamab, lenalidomide, and rituximab in relapsed or refractory follicular lymphoma (inMIND): a global, phase 3, randomised controlled trial
6小时前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT
3个月前
已完结
Treatment of Relapsed and Refractory Follicular Lymphoma: Which Treatment for Which Patient for Which Line of Therapy?
3个月前
已关闭
Frontline treatment of follicular lymphoma: What will it take to change current practice?
3个月前
已完结
Clinical Characteristics, Treatment Responses and Outcomes of Light Chain Multiple Myeloma
3个月前
已完结
Bispecific T-cell engager therapy for multiple myeloma
4个月前
已关闭
Bispecific T-cell engager therapy for multiple myeloma
4个月前
已关闭
Combination Strategies with Menin Inhibitors for Acute Leukemia
4个月前
已完结
Association of Selinexor Dose Reductions With Clinical Outcomes in the BOSTON Study
5个月前
已完结
皖公网安备34019202002308
